Search

Vaccines reduce the risk of developing COVID-19 — but studies disagree on their protective effect against long COVID. Vaccines reduce the risk of developing COVID-19 — but studies disagree on their protective effect against long COVID.

Data from almost 20 countries suggest that many callers were anxious and lonely rather than experiencing abuse or suicidal impulses. Data from almost 20 countries suggest that many callers were anxious and lonely rather than experiencing abuse or suicidal impulses.

The government’s decision to ease requirements will lower the cost of field trials, but does not yet address the path to market. The government’s decision to ease requirements will lower the cost of field trials, but does not yet address the path to market.

In this four-part podcast series, Nature follows two scientists to find what it takes to launch a research lab. Nature follows two scientists to find what it takes to launch a research lab.

The search for a CRISPR enzyme’s ancestors has revealed more than one million potential genome-editing tools. The search for a CRISPR enzyme’s ancestors has revealed more than one million potential genome-editing tools.

Scientists are trying to understand why a small number of people develop a mysterious clotting disorder after receiving a COVID jab. Scientists are trying to understand why a small number of people develop a mysterious clotting disorder after receiving a COVID jab.

Study provides hints about the factors that govern reproductive lifespan — and how they could eventually be harnessed to extend fertility. Study provides hints about the factors that govern reproductive lifespan — and how they could eventually be harnessed to extend fertility.

World Health Organization committee says it’s too soon to allow heritable gene editing, but points to paths forward for other applications. World Health Organization committee says it’s too soon to allow heritable gene editing, but points to paths forward for other applications.

Climate strikes, marsquakes and gaming AIs are among the year’s top stories. Climate strikes, marsquakes and gaming AIs are among the year’s top stories.

After finally gaining traction as a potential treatment for certain genetic disorders, gene therapy tackles the challenge of sickle-cell disease. After finally gaining traction as a potential treatment for certain genetic disorders, gene therapy tackles the challenge of sickle-cell disease.

Strategy uses a combination of parasites and medicines to generate immunity while avoiding symptoms. Strategy uses a combination of parasites and medicines to generate immunity while avoiding symptoms.

Administering gene-editing treatment directly into the body could be a safe and effective way to treat a rare, life-threatening condition. Administering gene-editing treatment directly into the body could be a safe and effective way to treat a rare, life-threatening condition.

Older people who waited 11–12 weeks for their second jab had higher peak antibody levels than did those who waited only 3 weeks. Older people who waited 11–12 weeks for their second jab had higher peak antibody levels than did those who waited only 3 weeks.

Scientists are investigating rare blood clots to ask if they could be linked to the Johnson & Johnson and Oxford-AstraZeneca coronavirus vaccines. Hear the latest science from the coronavirus pandemic.

What sort of system nurtures a decades-long programme of deliberately infecting children and prisoners with a dangerous disease? What sort of system nurtures a decades-long programme of deliberately infecting children and prisoners with a dangerous disease?

Drugs like molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world. Drugs like molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world.

How a win in the Supreme Court challenged a linchpin of the genetic-testing industry. How a win in the Supreme Court challenged a linchpin of the genetic-testing industry.

Uptake in the United States has been low, despite several authorized therapies and promising clinical trial results. Hear the latest science from the coronavirus pandemic.

US regulators have authorized Johnson & Johnson’s vaccine — which does not require a booster shot, and could simplify the logistics of mass vaccination. US regulators have authorized Johnson & Johnson’s vaccine — which does not require a booster shot, and could simplify the logistics of mass vaccination.

The science behind how and when to give vaccines doses. Hear the latest science from the coronavirus pandemic.

Combining different coronavirus shots could speed immunization campaigns — and even boost immune response. Combining different coronavirus shots could speed immunization campaigns — and even boost immune response.

Large study of UK health-care workers suggests that most people are immune for months after catching COVID-19 for the first time. Large study of UK health-care workers suggests that most people are immune for months after catching COVID-19 for the first time.

A book from the Oxford–AstraZeneca team, and a documentary, go behind the scenes in the race to vaccinate the world. A book from the Oxford–AstraZeneca team, and a documentary, go behind the scenes in the race to vaccinate the world.

With vaccination campaigns under way in some countries while others weigh the options, Nature looks at the evidence for vaccinating younger people. With vaccination campaigns under way in some countries while others weigh the options, Nature looks at the evidence for vaccinating younger people.

A malaria vaccine not only has achieved record-setting protection in a large trial, but also spurred the UK’s COVID-19 vaccine effort.

Two RNA vaccines will be useful as US infections surge, but the speedy authorizations complicate clinical trials. Two RNA vaccines will be useful as US infections surge, but the speedy authorizations complicate clinical trials.

The coronavirus pandemic shaped the year in research — from vaccines and treatments to campus shutdowns and virtual meetings.

The Pfizer–BioNTech vaccine has passed safety and efficacy tests — but researchers still have many questions about how this and other vaccines will perform as they’re rolled out to millions of people. The Pfizer–BioNTech vaccine has passed safety and efficacy tests — but researchers still have many questions about how this and other vaccines will perform as they’re rolled out to millions of people.

Around the world, COVID death rates are falling, but why? Hear the latest science from the coronavirus pandemic.

Hard-won experience, changing demographics and reduced strain on hospitals are all possibilities — but no one knows how long the change will last. Hard-won experience, changing demographics and reduced strain on hospitals are all possibilities — but no one knows how long the change will last.

Researchers fear that vaccines might not be as effective in people who are obese, a population already highly vulnerable to COVID-19. Researchers fear that vaccines might not be as effective in people who are obese, a population already highly vulnerable to COVID-19.